Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher M Rubino

Showing results (31-40 of 68) with videos related to

Pageof 7
Sort By:
Antimicrobial Agents and Chemotherapy|December 14, 2011
Frequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statisticsPaul G Ambrose, Jeffrey P Hammel, Sujata M Bhavnani, et al.
Diagnostic Microbiology and Infectious Disease|September 19, 2007
Pharmacokinetics and pharmacodynamics of gatifloxacin in children with recurrent otitis media: application of sparse sampling in clinical developmentChristopher M Rubino, Paul Ambrose, Brenda Cirincione, et al.
Antimicrobial Agents and Chemotherapy|January 31, 2018
Norepinephrine in Combination with Antibiotic Therapy Increases both the Bacterial Replication Rate and Bactericidal ActivityPaul G Ambrose, Brian D VanScoy, John Adams, et al.
Antimicrobial Agents and Chemotherapy|November 21, 2024
Population pharmacokinetic analyses for sulbactam-durlobactam using Phase 1, 2, and 3 dataAnthony P Cammarata, M Courtney Safir, Michael Trang, et al.
The Journal of Antimicrobial Chemotherapy|November 14, 2024
The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometricsDavid Andes, Roger J Brüggemann, Shawn Flanagan, et al.
Antimicrobial Agents and Chemotherapy|October 5, 2011
Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumoniaChristopher M Rubino, Sujata M Bhavnani, Alan Forrest, et al.
Antimicrobial Agents and Chemotherapy|February 14, 2018
Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult SubjectsChristopher M Rubino, Sujata M Bhavnani, Jeffery S Loutit, et al.
Antimicrobial Agents and Chemotherapy|March 21, 2018
Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrataJustin C Bader, Elizabeth A Lakota, Shawn Flanagan, et al.
Antimicrobial Agents and Chemotherapy|December 7, 2011
Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecyclineSujata M Bhavnani, Christopher M Rubino, Jeffrey P Hammel, et al.
Journal of Clinical Pharmacology|August 3, 2013
Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumoniaScott A Van Wart, Alan Forrest, Tatiana Khariton, et al.
Pageof 7

Showing results (31-40 of 68) with videos related to

Sort By:
Pageof 7
Antimicrobial Agents and Chemotherapy|December 14, 2011
Frequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statisticsPaul G Ambrose, Jeffrey P Hammel, Sujata M Bhavnani, et al.
Diagnostic Microbiology and Infectious Disease|September 19, 2007
Pharmacokinetics and pharmacodynamics of gatifloxacin in children with recurrent otitis media: application of sparse sampling in clinical developmentChristopher M Rubino, Paul Ambrose, Brenda Cirincione, et al.
Antimicrobial Agents and Chemotherapy|January 31, 2018
Norepinephrine in Combination with Antibiotic Therapy Increases both the Bacterial Replication Rate and Bactericidal ActivityPaul G Ambrose, Brian D VanScoy, John Adams, et al.
Antimicrobial Agents and Chemotherapy|November 21, 2024
Population pharmacokinetic analyses for sulbactam-durlobactam using Phase 1, 2, and 3 dataAnthony P Cammarata, M Courtney Safir, Michael Trang, et al.
The Journal of Antimicrobial Chemotherapy|November 14, 2024
The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometricsDavid Andes, Roger J Brüggemann, Shawn Flanagan, et al.
Antimicrobial Agents and Chemotherapy|October 5, 2011
Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumoniaChristopher M Rubino, Sujata M Bhavnani, Alan Forrest, et al.
Antimicrobial Agents and Chemotherapy|February 14, 2018
Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult SubjectsChristopher M Rubino, Sujata M Bhavnani, Jeffery S Loutit, et al.
Antimicrobial Agents and Chemotherapy|March 21, 2018
Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrataJustin C Bader, Elizabeth A Lakota, Shawn Flanagan, et al.
Antimicrobial Agents and Chemotherapy|December 7, 2011
Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecyclineSujata M Bhavnani, Christopher M Rubino, Jeffrey P Hammel, et al.
Journal of Clinical Pharmacology|August 3, 2013
Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumoniaScott A Van Wart, Alan Forrest, Tatiana Khariton, et al.
Pageof 7